Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.
News|Articles|April 17, 2026
ACOG updates guidance for evaluating postmenopausal bleeding
Author(s)Joshua Fitch, Senior Editor
Fact checked by: Benjamin P. Saylor
According to ACOG, approximately 90% of patients diagnosed with endometrial cancer have postmenopausal bleeding. Read more on the College's updated recommendations below.
Advertisement
Advertisement
Since approximately 90% of patients diagnosed with endometrial cancer have postmenopausal bleeding, and because of a steady increase in endometrial cancer incidence in recent decades, the American College of Obstetricians & Gynecologists (ACOG) has released updated guidance for evaluating postmenopausal bleeding.1
Related to this article
Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.
NK receptor antagonists significantly improved sleep disturbance in menopausal women at 4, 12, and 24 weeks in a meta-analysis of RCTs.
Perimenopausal women who were more physically active had significantly lower symptom burden across all domains, a study of 1808 Flo app users found.
JoAnn V. Pinkerton, MD, MSCP, reviews 4 pooled elinzanetant analyses from OASIS presented at The Menopause Society Annual Meeting 2026, spanning late perimenopause, sleep, VMS reduction, and safety.
Perimenopausal women over-reported total sleep time by a mean of 35.3 minutes and under-reported wake time compared with Fitbit data.
Elinzanetant cut moderate-to-severe VMS frequency by ≥50% in 66.9% of US participants compared with 40.5% on placebo.
Open-ended questions help ob-gyns untangle GSM and low desire and build adherence-focused treatment plans, according to Sheryl Kingsberg, PhD.
Advertisement
Advertisement